Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Jessica Madera-McDonough"'
Autor:
Roger S. McIntyre, Pedro Such, Murat Yildirim, Jessica Madera-McDonough, Na Jin, Suzanne Watkin, Zhen Zhang, Frank Larsen, Matthew Harlin
Publikováno v:
Therapeutic Advances in Psychopharmacology, Vol 14 (2024)
The purpose of this summary is to explain key findings from a study that included people with bipolar I disorder, as described in two separate articles (see the ‘Further Information’ section for more details). The study compared a new formulation
Externí odkaz:
https://doaj.org/article/8488187a75154f3f9759df68707e2db3
Autor:
Matthew Harlin, Murat Yildirim, Pedro Such, Jessica Madera-McDonough, Michael Jan, Na Jin, Suzanne Watkin, Frank Larsen
Publikováno v:
CNS Drugs. 37:337-350
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9d317b45a88f1e040068af542be2aa82
https://doi.org/10.1007/s40263-023-00996-8
https://doi.org/10.1007/s40263-023-00996-8
Autor:
Lenard A, Adler, Julie, Adams, Jessica, Madera-McDonough, Eva, Kohegyi, Mary, Hobart, Denise, Chang, Mark, Angelicola, Robert, McQuade, Michael, Liebowitz
Publikováno v:
Journal of Clinical Psychopharmacology. 42:429-439
Centanafadine is an inhibitor of norepinephrine, dopamine, and serotonin reuptake transporters under investigation for the treatment of attention-deficit/hyperactivity disorder (ADHD).Two phase 3 randomized, double-blind, placebo-controlled, parallel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a536bae836029022f18b069243588f20
https://doi.org/10.1097/jcp.0000000000001575
https://doi.org/10.1097/jcp.0000000000001575
Autor:
Matthew Harlin, Murat Yildirim, Pedro Such, Jessica Madera-McDonough, Michael Jan, Frank Larsen
Publikováno v:
CNS Spectrums. 28:237-238
IntroductionAripiprazole 2-month ready-to-use 960 mg (Ari 2MRTU 960) is a new long-acting injectable (LAI) antipsychotic formulation for gluteal administration every 2 months, intended for the treatment of schizophrenia and maintenance monotherapy tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a37462e35d2125fef43d89ff0b1a22eb
https://doi.org/10.1017/s1092852923001670
https://doi.org/10.1017/s1092852923001670
Safety And Efficacy of Aripiprazole 2-Month Ready-to-Use 960 mg in Adult Patients With Schizophrenia
Publikováno v:
CNS Spectrums. 28:242-243
BackgroundAripiprazole 2-month ready-to-use 960 mg (Ari 2MRTU 960) is a new long-acting injectable (LAI) antipsychotic formulation for gluteal administration every 2 months. This 32-week trial evaluated the safety, pharmacokinetics, and efficacy of m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::548df845274ad515f56fb692306c927d
https://doi.org/10.1017/s109285292300175x
https://doi.org/10.1017/s109285292300175x
Autor:
John M. Kane, Murat Yildirim, Jessica Madera-McDonough, Celso Arango, Andrea Fagiolini, Philip Gorwood, Navdeep Sahota, Christoph U. Correll
Publikováno v:
CNS Spectrums. 28:251-252
Functional recovery is a treatment goal that goes beyond symptomatic remission and encompasses multiple aspects of schizophrenia patients’ lives, including quality of life, physical, and mental functioning. There is evidence that long-acting inject
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0fc5b1460e6ec642ab5a2d6d137b5b06
https://doi.org/10.1017/s109285292300192x
https://doi.org/10.1017/s109285292300192x
Autor:
John M. Kane, Murat Yildirim, Jessica Madera-McDonough, Celso Arango, Andrea Fagiolini, Philip Gorwood, Navdeep Sahota, Christoph U. Correll
Publikováno v:
CNS Spectrums. 28:252-252
Schizophrenia is among the top ten causes of years lost due to disability. Goals of treatment are evolving beyond remission of psychotic symptoms to include physical and mental functioning, quality of life, and long-term functional recovery. Evidence
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::29a66c131ce7bc9945f65e6aa3bdde1b
https://doi.org/10.1017/s1092852923001931
https://doi.org/10.1017/s1092852923001931
Publikováno v:
CNS Spectrums. 28:256-256
IntroductionAntipsychotic treatment can help improve outcomes in schizophrenia by reducing the risk of relapse and psychiatric hospitalization, and increasing rates of remission and recovery, particularly when used early in the disease course. Howeve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5387e2ec0df84f286e8834a6a3e88dc2
https://doi.org/10.1017/s1092852923002018
https://doi.org/10.1017/s1092852923002018
Publikováno v:
CNS Spectrums. 28:244-244
BackgroundAripiprazole 2-month ready-to-use 960 mg (Ari 2MRTU 960) is a new long-acting injectable (LAI) antipsychotic formulation for gluteal administration every 2 months. This 32-week trial evaluated the safety, pharmacokinetics, and efficacy of m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5afbeca3037862681be7d66cb74f6d12
https://doi.org/10.1017/s1092852923001785
https://doi.org/10.1017/s1092852923001785
Publikováno v:
CNS Spectrums. 28:256-256
IntroductionAripiprazole 2-month ready-to-use 960 mg (Ari 2MRTU 960) is a new long-acting injectable (LAI) antipsychotic formulation for gluteal administration every 2 months, intended for the treatment of schizophrenia and maintenance monotherapy tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::db3c42c635bba30e0ecfede97dec4cf7
https://doi.org/10.1017/s1092852923002006
https://doi.org/10.1017/s1092852923002006